Our missions are to explore the medical and industrial potential of iPS cells, and to bring innovative technology solutions by providing expertise in all stages of project development and translation.INGESTEM aims to coordinate and structure different steps involved in the development stem cells used either for drug screening or for protocols of regenerative medicine with the following strategies:- Creation of a “research” biobank of human and animal induced pluripotent stem cells (iPS) and embryonic stem cells (ES)- Development of a french registry of iPS cell lines qualified with international standards, including clinical and biological annotations- Cell and tissue engineering- Risk analysis and characterization of products from cell engineering- Standardization of protocols and automated production- Transgenic animal models- Modeling of human monogenic and polygenic genetic diseases, drug discovery by high throughput screening.- Therapeutic models with design and validation of preclinical models to the production of Advanced-Therapy Medicinal Products (ATMPs) for early clinical trials phase I-II.